FGF23 and chronic kidney disease: In spite of reducing serum FGF-23 levels improving bone quality in CKD mice (Sun et al., 2015), anti-FGF-23 antibodies treatment was found to significantly augment phosphate levels, vascular calcification, and death risk in an experimental CKD model (Shalhoub et al., 2012).